Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: equality impact assessment - guidance review (PDF 155 KB)

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final appraisal determination information

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final appraisal document (PDF 441 KB)

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: committee papers information

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: committee papers (PDF 11.42 MB)

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final scope (PDF 105 KB)

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: final matrix (PDF 100 KB)

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: NICE response to comments on the draft scope and provisional matrix (PDF 251 KB)

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate [ID662]: equality impact assessment - scoping (PDF 119 KB)

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate: draft scope for consultation (pre-referral) - March 2014 (PDF 113 KB)

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate: provisional matrix (pre-referral) - March 2014 (PDF 99 KB)